Abstract
The aim of the research is to analyze and assess the parallel export of medicines with annual sales of >3 million BGN for treatment of oncological diseases from Bulgaria in the year 2016. Risk assessment for the shortage of life-saving medicinal products. A documentary method and analysis was used to compare the quantity and value of oncological medicinal products sold to distributors in Bulgaria in 2016 and paid by the National Health Insurance Fund (NHIF), reported by two independent sources - IMS Health (IMS) and National Health Insurance Fund (NHIF). The study included products with annual sales of> 3 million BGN. The economic analysis carried out estimated the value of the parallel export of medical products for treatment of cancer from Bulgaria in 2016 at 43.2 million BGN. Products of 5 pharmaceutical manufacturers account for 87.2% of the value of the parallel export: Roche (52.8%) - bevacizumab, trastuzumab, rituximab , erlotinib, pertuzumab, vemurafenib; BMS (14.3%) - dasatinib; Bayer (9.2%) - sorafenib, Novartis (6.2%) - everolimus, nilotinib, pazopanib; Astellas (4.7%) – enzalutamide. Conclusions: This study does not reveal any evidence of either medical product shortage nor limited access to treatment for patients due to lack of access to drug therapy in Bulgaria
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
